+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

High dose therapy and autologous stem cell transplantation for adults with Hodgkins disease in first relapse after chemotherapy Conventional dose salvage therapy prior to ASCT has no effect on outcome Results from the EBMT



High dose therapy and autologous stem cell transplantation for adults with Hodgkins disease in first relapse after chemotherapy Conventional dose salvage therapy prior to ASCT has no effect on outcome Results from the EBMT



Blood 88(10 Suppl. 1 Part 1-2): 486A




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 031688896

Download citation: RISBibTeXText


Related references

Adult Burkitts and Burkitt-like non-Hodgkins lymphoma Favourable outcome for patients undergoing high dose therapy and autologous stem cell transplantation in first remission or chemosensitive relapse Results from the EBMT. Blood 86(10 Suppl. 1): 211A, 1995

High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplantation 27(9): 933-937, 2001

Patterns of relapse and survival following high dose therapy and stem cell transplantation for non-Hodgkins lymphoma Results from the EBMT. Blood 92(10 Suppl. 1 Part 1-2): 415A, Nov 15, 1998

Long term follow up in relapsed Hodgkin's disease (HD): Updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). Journal of Clinical Oncology 23(16_Suppl): 6508-6508, 2016

High-dose chemotherapy and autologous hematopoietic stem cell transplantation does not increase the risk of second neoplasms for patients with Hodgkins lymphoma A comparison of conventional therapy alone versus conventional therapy followed by AHSCT. Blood 102(11): 116a-117a, November 16, 2003

MAMI salvage therapy and high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in refractory or relapsing non Hodgkins lymphoma. Blood 88(10 Suppl. 1 Part 1-2): 281B, 1996

PACE-BOM salvage prior to high dose therapy and autologous stem cell transplantation for aggressive non-Hodgkins lymphoma An active well-tolerated out-patient regimen. British Journal of Cancer 80(Suppl. 2): 54, 1999

HD-RI First results of a randomized trial comparing aggressive chemotherapy with high-dose therapy and hematopoietic stem cell transplantation in patients with chemosensitive relapse of Hodgkins disease. Blood 90(10 Suppl. 1 Part 1): 115A, Nov 15, 1997

Phase I Study of Involved Field Radiation Therapy Preceding High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with High Risk Hodgkins Disease and Non-Hodgkins Lymphoma. Blood 100(11): Abstract No 3405, November 16, 2002

High-dose therapy and autologous stem cell transplantation in Hodgkins disease patients who progress after primary chemotherapy. Bone Marrow Transplantation 15(Suppl. 1): S229, 1995

Salvage high-dose chemotherapy with allogeneic stem-cell support for relapse or incomplete remission following high-dose chemotherapy with autologous stem-cell transplantation for hematologic malignancies. Tecnologica. Map Supplement. Blue Cross and Blue Shield Association. Medical Advisory Panel: 16-19, 2000

Treatment of relapsed non-Hodgkins lymphoma after high dose beam chemotherapy and autologous stem cell transplantation by high-dose BU/CY and salvage stem cell transplantation. Blood 88(10 Suppl. 1 Part 1-2): 268B, 1996

A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation. Bone Marrow Transplantation 29(8): 647-652, 2002

Chemosensitive transformed follicular non-Hodgkins lymphoma is a firm indication for high-dose therapy and autologous stem cell transplantation A study from the EBMT registry. Blood 88(10 Suppl. 1 Part 1-2): 685A, 1996

High-dose therapy autologous stem cell transplantation vs conventional therapy for patients with advanced Hodgkin's disease responding to first-line therapy: analysis of clinical characteristics of 51 patients enrolled in the HD01 protocol. EBMT/ANZLG/Intergroup HD01 Trial. Leukemia 10(Suppl. 2): S69-S71, 1996